The National Institutes of Health (NIH) has awarded Excelimmune a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection.
The company said that the SBIR grant will fund a project entitled ‘The Creation of a Human Recombinant Polyclonal Antibody Therapy against C. difficile’, which will be conducted at Excelimmune’s new facility in Woburn, and in consortium with the Roger Williams Medical Center in Providence, RI.
Quinton Zondervan, president and CEO of Excelimmune, said: “This grant is an important milestone for our company. The support from the NIH will allow us to expand and accelerate our development program focused on using human recombinant polyclonal antibodies to fight infectious disease.”
Excelimmune has developed a novel platform for the creation of human recombinant polyclonal antibodies. Using this platform, Excelimmune is targeting bacterial pathogens that cause disease, including C. difficile.